Multilab is a Brazilian company, founded in 1988, that is today part of one of the largest pharmaceutical groups in the world: Takeda.Watch our institutional video
With over 27 years in the market, we are a Brazilian company that is today part of one of the largest pharmaceutical groups in the world: Takeda.
As a result of the acquisition, which occurred in July 2012, Takeda joined the list of the ten biggest pharmaceutical companies in Brazil and ranks among the top 20 in the world.
Our industrial complex is located in the city of São Jerônimo – 75 km from Porto Alegre, in the state of Rio Grande do Sul – with an area of 18,000 m².
Here, there are around 550 professionals from the company devoted to research, development, production and distribution of pharmaceutical drugs, in a wide range of therapeutic areas. Our drugs are divided into the following lines: Prescription, Generic, OTC and Hospital.
You can follow Multilab’s rapid growth, development and expansion until today on our timeline.
Multilab started its operation with only three employees in a 14 m² production space, where tea and herb-based medications were produced.
FIRST INDUSTRIAL PLANT WITH 12,000 M² AND 30 EMPLOYEES
The first industrial plant had an area of 1,200 m² and 30 employees. Production was also diversified and Multilab started launching its first similar drugs in capsules and tablets, and expanded its sales region, serving all the states in the south region of Brazil.
CONSTRUCTION OF THE NEW FACTORY
The factory structure was already insufficient. It was necessary to plan a new factory that would be owned by the company, with the size, structure and physical area to meet current production needs and future expansions, as well as comply with all the Good Manufacturing Practices requirements that were being implemented by ANVISA (National Health Surveillance Agency).
LAUNCH OF MULTIGRIP AND LOZEPREL
At the turn of the century, Multilab launched two of its main products: an anti-flu drug, Multigrip¹, and an anti-ulcer drug, Lozeprel². Up until today, the products are market leaders in their categories. Reference: 1) IMS Health. Pharmaceutical Market Brazil Audit; units, reais PMB FEB/2016. 2) IMS Health. Pharmaceutical Market Brazil Audit; units, APR/2016.
EXPANSION - SÃO JERÔNIMO PLANT
In February, Multilab inaugurated its new factory, in the city of São Jerônimo, 75 km from Porto Alegre, in an area of 50,000 m², fully approved by ANVISA (National Health Surveillance Agency) and certified by GMP (Good Manufacturing Practices).
Takeda acquired Multilab, which then became part of a global company, the largest pharmaceutical company in Japan and 12th largest in the world. It was the beginning of a more prosperous stage that we are currently experiencing. Multilab received new investments in machinery and technology, further preparing it to launch various drugs in the coming years.
Our actions and decisions focus on our four strategic priorities, in the following order:
Provide quality products for people’s health and well-being, at affordable prices, obtained in a sustainable way, as well as seek continuous improvement, through the work of people who love what they do.
Better Health, Brighter Future
We serve the needs of our patients, wherever they are. We earn the trust of society and customers through Takeda-ism. We are recognized as best in class because of agility and innovation, qualities that enable us to constantly develop our products and deliver growth year on year.
Aligned with the Takeda culture, Multilab's principles are integrity, fairness, honesty and perseverance – our corporate philosophy known to us as Takeda-ism. Takeda-ism is a set of beliefs and practices that have evolved since the founding of the company in 1781. Even in the early days of the company, we know that the founder Takeda, Chobei I, believed that fairness and honesty were essential for the company's success. Formulated in 1940, by Chobei V, we can trace Takeda-ism as the global corporate philosophy of Takeda that represents our principles and strengths.
In addition to Takeda-ism, we always work with the patient at the center of our activities. This approach started with our global CEO, Christophe Weber, and has increasingly gained strength. "Above all else, we want our employees and leaders to put the patient in first place, reflecting as to whether we are doing the right thing for physicians who are caring for patients," says Weber.
MBS Multilab Business School
MBS IS THE MULTILAB BUSINESS SCHOOL
MBS is the Multilab Business School. It is built on an innovative concept (Corporate Pharma University) with a unique and exclusive study method for each client working in Multilab's business. It is comprised of four stages (Alpha, Beta, Gamma and Delta) and has already trained employees from networks around the country.